Apellis Pharmaceuticals, Inc.

APLS · Nasdaq · SIC 2834: Pharmaceutical Preparations
97
SEC Filings

Business Summary

PART I Item 1. B usiness. Overview We are a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system. We believe this approach has the potential to effectively control diseases with high unmet need that are driven by excessive complement activation. We currently have two marketed d...

Next Earnings

Q2 FY2026 — expected 2026-08-22

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionAPLSdiscussed_in_filing Cybersecurity
topic_mentionAPLSdiscussed_in_filing Cybersecurity
topic_mentionAPLSdiscussed_in_filing Healthcare & Bio
topic_mentionAPLSdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-02-242025-12-310001193125-26-065179EDGAR122K words
2025-02-282024-12-310000950170-25-029507EDGAR—
2024-02-272023-12-310000950170-24-020614EDGAR—
2023-02-212022-12-310000950170-23-003438EDGAR—
2022-02-282021-12-310001564590-22-007606EDGAR—
2021-02-252020-12-310001564590-21-008800EDGAR—
2020-02-272019-12-310001564590-20-007350EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-10-302025-09-300001193125-25-257374EDGAR30K words
2025-07-312025-06-300000950170-25-100545EDGAR—
2025-05-072025-03-310000950170-25-064976EDGAR—
2024-11-052024-09-300000950170-24-121062EDGAR—
2024-08-012024-06-300000950170-24-088938EDGAR—
2024-05-072024-03-310000950170-24-053921EDGAR—
2023-11-012023-09-300000950170-23-057117EDGAR—
2023-07-312023-06-300000950170-23-035935EDGAR—
2023-05-042023-03-310000950170-23-017819EDGAR—
2022-11-072022-09-300000950170-22-022606EDGAR—
2022-08-082022-06-300000950170-22-015500EDGAR—
2022-05-042022-03-310000950170-22-007374EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-310001193125-26-134916EDGAR67K words
2026-03-020001193125-26-084156EDGAR—
2026-01-120001193125-26-010540EDGAR—
2025-07-010001193125-25-153429EDGAR—
2025-06-040001193125-25-134886EDGAR—
2025-04-210001193125-25-086304EDGAR—
2025-01-130001193125-25-005052EDGAR—
2024-08-080001193125-24-196465EDGAR—
2024-06-050001193125-24-155179EDGAR—
2024-05-140001193125-24-137743EDGAR—

97 total filings indexed. 68 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001492422
TickerAPLS
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 04d9f02ea2e2e4159eed598e0a5ae3cfe9a5bd9ef5ed78c8615177a20c452568
parent: 180bde739e21aa027437c8e1ad87c8fd9f23a8287d0f16023f6762f5afaad5c3
content hash: 5db56751b9a910e46af93bc3dcb7267672d61ed1913e4d9a615c2dd10b38946c
signed: 2026-04-13T04:43:41.299Z
sources: 19 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf